Status:

COMPLETED

Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population

Lead Sponsor:

Natural Immune Systems Inc

Conditions:

Anemia

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to evaluate the timing and magnitude of improvements to red blood cell health associated with consumption of Jobelyn™.

Detailed Description

From past history, case studies in Nigeria, as well as testimonials from all over the world, have shown a robust increase in hemoglobin within a few weeks in people with serious cases of anemia presen...

Eligibility Criteria

Inclusion

  • 18-65 year old people of either gender
  • Borderline anemic (This is compensated for altitude of study location):
  • Hemoglobin level at or below 13.5 g/dL(women)
  • Hemoglobin level at or below 15.5 g/dL(men)

Exclusion

  • Known diagnosis with pernicious or other megaloblastic anemias, aplastic, sickle cell, thalassemia, autoimmune hemolytic anemias;
  • Known diagnosis with Hashimoto's Disease;
  • Known chronic kidney disease;
  • Rheumatoid arthritis;
  • Splenectomy;
  • Serious active illness within past 12 months;
  • Active cancer and/or chemotherapy within the last 12 months;
  • Major surgery during past 8 weeks;
  • Scheduled surgery during study;
  • Received blood transfusion during the past 8 weeks;
  • Having donated blood for 6 weeks prior to study, or planning to donate blood during the 8 week study;
  • Distance athlete;
  • Unable to commit to staying on a constant regimen of medication and supplements for the duration of the study, with the exception of changes to medication needed for optimal care;
  • Changes to prescription medication within 2 weeks before starting the study;
  • Participation in other clinical trials during the month before this study begins;
  • Participating in other clinical trials during this study;
  • Current use of any dietary supplements that may affect hemoglobin levels; Vitamin B12 (over 500 mcg), Iron (over 100mg), or any other dietary supplement that, in the opinion of the investigator, may affect hemoglobin levels;
  • Currently experiencing intense stressful events/ life changes that would negatively affect compliance;
  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery is not a problem, including appendix and gallbladder removal);
  • Females of child-bearing potential: Pregnant, nursing, or trying to become pregnant;
  • Food allergies related to sorghum or rice.

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT01828060

Start Date

April 1 2013

Last Update

September 25 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NIS Labs

Klamath Falls, Oregon, United States, 97601